Results 71 to 80 of about 25,910 (235)

Estimated central blood volume in cirrhosis [PDF]

, 1992
The estimated central blood volume (i.e., blood volume in the heart cavities, lungs and central arterial tree) was determined by multiplying cardiac output by circulatory mean transit time in 19 patients with cirrhosis and compared with sympathetic ...
Arendt, Arroyo, Bendtsen, Bichet, Bichet, Bonkovsky, Bosch, Campbell, Christensen, Epstein, Gerbes, Gerbes, Gerbes, Gerbes, Goetz, Gossmann, Groszmann, Henriksen, Henriksen, Henriksen, Henriksen, Henriksen, Henriksen, Keller, Kopp, Kostreva, Lassen, Liebermann, Nicholls, Panos, Rector, Rector, Ring-Larsen, Rodriguez-Roisin, Rowell, Sagawa, Salerno, Schlant, Schrier, Sherlock   +39 more
core   +1 more source

Phenotyping patients with chronic obstructive pulmonary disease and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher, Felix Lindberg, Lina Benson, Camilla Hage, Ulf Dahlström, Stephan Rosenkranz, Francesco Cosentino, Giuseppe M.C. Rosano, Stefan Blankenberg, Paulus Kirchhof, Frieder Braunschweig, Lars H. Lund, Gianluigi Savarese   +12 more
wiley   +1 more source

Detection of C-type natriuretic peptide (CNP) transcript in the rat heart and immune organs [PDF]

, 1993
Previous studies suggested the expression of mRNA, coding for CNP, exclusively in the central nervous system. In the present study, using the polymerase chain reaction (PCR) technique instead of the less sensitive Northern blot hybridization, CNP ...
Gerbes, Alexander L., Nemer, M., Schulz, R., Vollmar, Angelika M.   +3 more
core   +1 more source

Identification and solubilization of atrial natriuretic factor receptors in human placenta

Biochemical and Biophysical Research Communications, 1986
Specific high affinity 125I-atrial natriuretic factor binding sites have been identified in human placental membranes. Using the nonionic detergent, Triton X-100, these binding sites were quantitatively solubilized and retained binding activity. In the solubilized preparation, the macromolecular component that binds atrial natriuretic factor is a 160 ...
openaire   +2 more sources

eGFR slope as predictor of mortality in heart failure patients

ESC Heart Failure, Volume 12, Issue 2, Page 1217-1226, April 2025.
Abstract Aims Heart failure (HF) leads to an imbalance between heart and kidney function, resulting in poor outcomes. However, the prognostic significance of the estimated glomerular filtration rate (eGFR) trajectory in HF patients remains unclear. We analysed electronic health records (EHRs) of real‐world HF patients, assessing eGFR trajectories and ...
Sofie Verstreken, Monika Beles, Clara L. Oeste, Ana Moya, Imke Masuy, Riet Dierckx, Ward Heggermont, Jeroen Dauw, Dries Hens, Jozef Bartunek, Marc Vanderheyden   +10 more
wiley   +1 more source

Atrial natriuretic factor [PDF]

, 1987
The discovery of the first well-defined natriuretic hormone, the Atrial Natriuretic Factor (ANF), has prompted research on its impact on volume regulation in health and disease.
A.L. Gerbes, Ames, Anderson, Anderson, Arendt, Arendt, Arendt, Arendt, Atlas, Ballermann, Ballermann, Barakat, Bichet, Bichet, Biollaz, Bompiani, Bonkovsky, Bourgoignie, Brabant, Bricker, Buckalew, Burghardt, Burnett, Campbell, Chartier, Conn, Cuneo, Currie, De Wardener, DeBold, DeBold, DeWardener, Epstein, Epstein, Epstein, Epstein, Epstein, Fernandez-Cruz, Forssmann, Fyhrquist, G. Paumgartner, Ganger, Gauer, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerzer, Gerzer, Ginés, Goodfriend, Hartshorne, Henry, Jimenez, Jüppner, Kisch, Kramer, Laffi, Lang, Laragh, Maack, Manning, Marin-Grez, Morgan, Naruse, Needleman, Needleman, Nishiuchi, Nozuki, Ogihara, R.M. Arendt, Renner, Richards, Richards, Richards, Riegger, Ring-Larsen, Rosoff, Sagnella, Sagnella, Salerno, Samson, Schafferhans, Shenker, Sherlock, Shimizu, Thibault, Tikkanen, Uehlinger, Valdivieso, Wambach, Weidmann, Wernze, Wilkinson, Wong, Yamaji, Zipser   +99 more
core   +1 more source

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang, Chunlan Deng, Xiaogang Guo, Hui Yan   +3 more
wiley   +1 more source

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch, Ali Zafari, Shofiqul Islam, Shun Fu Lee, Rajiv Sankaranarayanan, Stephen J Greene, Mamas A Mamas, Ambarish Pandey, Harriette GC Van Spall   +8 more
wiley   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source